Received Nov 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2H262 | — |
Incorrect route of administration/given it IV versus IM by accident; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a adult male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 2H262) for prophylaxis. On 21-OCT-2025, the patient received Boostrix (intravenous inf). On 21-OCT-2025, an unknown time after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Incorrect route of administration/given it IV versus IM by accident). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-OCT-2025 The registered nurse reported that TDAP had been given intravenously versus intramuscularly by accident. She called poison control, and they said they didn't see anything for a further reaction and that they suggested that she should call the manufacturer just to be on the safe side. Did not consent to follow-up.